This is a StreetInsider.com Premium Only Page

OptiNose (OPTN) – Globe Newswire

Apr 4, 2024 04:01 PM Optinose to Present at the Needham Virtual Healthcare Conference

Mar 15, 2024 03:34 PM XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Mar 7, 2024 07:00 AM Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Feb 29, 2024 04:40 PM Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Jan 18, 2024 12:00 PM Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Dec 6, 2023 07:00 AM Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Nov 22, 2023 09:00 AM Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 9, 2023 07:00 AM Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Oct 27, 2023 08:00 AM Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

Sep 22, 2023 09:01 AM Optinose to Present at the 2023 Cantor Global Healthcare Conference

Aug 10, 2023 07:00 AM Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Jul 27, 2023 07:00 AM Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Jun 16, 2023 04:08 PM Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023 01:00 PM Optinose to Present at the Jefferies Healthcare Conference

May 11, 2023 07:00 AM Optinose Reports First Quarter 2023 Financial Results and Operational Updates

May 4, 2023 07:00 AM Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

May 1, 2023 04:30 PM Optinose Announces Reporting Date for First Quarter 2023 Financial Results

Apr 18, 2023 08:00 AM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 12, 2023 04:00 PM Optinose to Present at the Needham Virtual Healthcare Conference

Mar 7, 2023 07:00 AM Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Feb 28, 2023 04:30 PM Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

Feb 21, 2023 07:00 AM Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion

Jan 31, 2023 07:00 AM Optinose Announces CEO Transition and Business Update

Dec 15, 2022 04:30 PM Optinose Appoints Paul Spence as Chief Commercial Officer

Dec 9, 2022 08:00 AM Optinose Announces Departure of Acting Chief Financial Officer

Nov 30, 2022 07:00 AM Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

Nov 21, 2022 08:30 AM Optinose Announces Pricing of Public Offering of Common Stock and Warrants

Nov 21, 2022 06:12 AM Optinose Announces Proposed Public Offering of Common Stock and Warrants

Nov 10, 2022 07:00 AM Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

Nov 9, 2022 03:00 PM Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

Nov 7, 2022 03:00 PM Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

Oct 21, 2022 07:00 AM Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

Sep 6, 2022 12:00 PM Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

Aug 11, 2022 07:00 AM Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

Aug 8, 2022 04:20 PM Optinose Announces Reporting Date for Second Quarter 2022 Financial Results

Jul 13, 2022 07:00 AM Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

Jul 8, 2022 07:00 AM Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

Jun 13, 2022 07:00 AM Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

Jun 3, 2022 07:00 AM Optinose Announces Departure of Chief Financial Officer

May 12, 2022 07:00 AM Optinose Reports First Quarter 2022 Financial Results and Operational Updates

May 5, 2022 05:00 PM Optinose Announces Reporting Date for First Quarter 2022 Financial Results

Apr 26, 2022 08:00 AM Optinose Announces Appointment of R. John Fletcher to the Board

Apr 8, 2022 08:30 AM Optinose to Present at the Needham Virtual Healthcare Conference

Mar 8, 2022 07:00 AM Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Mar 7, 2022 07:00 AM Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis

Mar 4, 2022 02:00 PM Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results

Dec 13, 2021 07:54 AM Optinose Announces Appointment of Two New Members to Board of Directors

Nov 23, 2021 07:00 AM Optinose to Present at the Piper Sandler Virtual Healthcare Conference

Nov 18, 2021 04:30 PM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2021 02:00 PM Optinose Announces Closing of $46.0 Million Public Offering of Common Stock